Sativex (GW-1000) for peripheral neuropathy

[Guest guest]

Abstract from Curr Opin Investig Drugs. 2004 Jul;5(7):748-54.

GW-1000. GW Pharmaceuticals.

PF.

University of Otago, Department of Pharmacology and Toxicology, School

of Medical Sciences, Dunedin, New Zealand.

GW Pharmaceuticals is developing GW-1000 (Sativex), a narrow ratio

delta9-tetrahydrocannabinol:cannabidiol product for the potential

treatment of multiple sclerosis, spinal cord injury, neurogenic pain and

peripheral neuropathy. In March 2003, the company filed for approval for

the treatment of MS with the UK Medicines Control Agency, and in May

2004, filed for new drug submission with Health Canada.